Eli Lilly & Co has announced a $27-billion expansion of its US manufacturing operations, adding four new sites and creating 13,000 jobs. This move aims to strengthen domestic supply chains and boost the production of drugs, Mounjaro and Zepbound. It aligns with a broader push to reduce pharmaceutical imports and improve the US healthcare sector.